The developments in the radiopharmaceuticals Market have been characterized as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as launches, expansion, enhancement as well as relocation. Inorganic growth strategies witnessed in the market were mergers & acquisitions, partnership, collaborations, alliance, and agreement & joint ventures. These activities have paved way for expansion of business and customer base of market players.
Bayer AG, and GE Healthcare – Notable Market Players in Radiopharmaceuticals Market
Market leaders operating in the market have undertaken various organic growth strategies in the radiopharmaceuticals market. The radiopharmaceuticals market majorly consists of the players Cardinal Health, GE Healthcare, Curium, Lantheus Medical Imaging, Bayer AG, Bracco Imaging, Eczacýbaþý-Monrol Nuclear Products, Nordion, Advanced Accelerator Applications, and NTP Radioisotopes. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaborations.
Below is the list of the growth strategies done by the players operating in the radiopharmaceuticals market:
| Year | News |
| Jul-2021 | Lantheus received U.S. FDA approval of PYLARIFY (piflufolastat F 18) injection, the first and only commercially available PSMA PET imaging agent for prostate cancer. PYLARIFY was developed to target PSMA, a protein that is overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells. |
| Jun-2021 | Curium has successfully completed the acquisition of the Austrian radiopharmaceuticals Company IASON, further expanding its footprint in Europe for its broad portfolio of life saving diagnostic solutions. |
| Jun-2021 | Bayer AG announced the acquisition of Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc. Through this acquisition, Bayer AG will obtain exclusive rights to a differentiated alpha radionuclide investigational compound based on actinium-225 and a small molecule directed towards prostate-specific membrane antigen (PSMA). |
| May-2021 | Telix entered a global clinical supply agreement with Eczacbacs -Monrol Nuclear Products Co. (Monrol) for the supply of no carrier added (NCA) lutetium-177 (177Lu), a key therapeutic isotope used in Telix’s portfolio of Molecularly Targeted Radiation (MTR) products. |
